Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1762-1769

  Adenis, A ^a   Blay, J Y ^b   Bui Nguyen, B ^c   Bouche O ^d   Bertucci, F ^e   Isambert, N ^f   Bompas, E ^g   Chaigneau, L ^h   Domont, J ⁱ   Ray Coquard, I ^b   Blesius A ⁱ   Van tine, B A ^j   Bulusu, V R ^k   Dubreuil, P ^l,m,n   Mansfield, C D ⁿ   Acin, Y ⁿ   Moussy, A ⁿ   Hermine, O ^n,o,p,q   Le Cesne, A ⁱ  

^a CENTRE OSCAR LAMBRET   (France)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT BERGONIÉ   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j USA   (United States)

^k ADDENBROOKE S HOSPITAL   (United Kingdom)

^l AIX MARSEILLE UNIVERSITY   (France)

^m AIX MARSEILLE UNIVERSITY   (France)

ⁿ AB Science   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p CNRS   (France)

^q IMAGINE INSTITUTE   (France)

more..

Author keywords

GIST; Imatinib resistant GIST; Phase II study; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; MASITINIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STEM CELL FACTOR RECEPTOR; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; EYELID EDEMA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TUMOR LOCALIZATION; VERY ELDERLY; VOMITING; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; MIDDLE AGED; MORTALITY; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; THIAZOLES; TREATMENT FAILURE;

EID: 84906847643     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu237     Document Type: Article

References (17)

1. Gastrointestinal Stromal Tumor Meta-Analysis Group GSTMA. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247-1253.
2. Novartis. Glivec: summary of product characteristics. URL: www.pharma.us. novartis.com/product/pi/pdf/gleevec_tabs.pdf (14 May 2014, date last accessed).
3. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
4. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011; 37: 75-88.
5. Demetri GD, Garrett CR, Schoffski P et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012; 18: 3170-3179.
6. Schwandt A, Wood LS, Rini B, Dreicer R. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2009; 2: 51-61.
7. Dubreuil P, Letard S, Ciufolini M et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009; 4: e7258.
8. Davis MI, Hunt JP, Herrgard S et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-1051.
9. Anastassiadis T, Deacon SW, Devarajan K et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1039-1045.
10. Le Cesne A, Blay JY, Bui BN et al. Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): five-year follow-up of the French Sarcoma Group phase II trial. J Clin Oncol 2012; 30 (suppl): abstr 10089.
11. Soria JC, Massard C, Magne N et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 2009; 45: 2333-2341.
12. Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011; 29: 2439-2442.
13. Wood LS. Managing the side effects of sorafenib and sunitinib. Commun Oncol 2006; 3: 558-562.
14. Seddon B, Reichardt P, Kang Y et al. Detailed analysis of survival and safety with sunitinib in a worldwide treatment-use trial of patients with advanced imatinibresistant/intolerant GIST. In Presented at the Connective Tissue Oncology Society (Abstr 34980). London, UK 2008.
15. Menard C, Blay JY, Borg C et al. Natural killer cell IFN-gamma levels predict longterm survival with imatinib mesylate therapy in gastrointestinal stromal tumorbearing patients. Cancer Res 2009; 69: 3563-3569.
16. Borg C, Terme M, Taieb J et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114: 379-388.
17. Auclair C, Tursz T, Zitvogel L. Use of specific inhibitors of tyrosine kinases for immunomodulation. WO2004026311 A2 (Patent) 2004.